Timothy Perera

3.2k total citations
31 papers, 1.3k citations indexed

About

Timothy Perera is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Timothy Perera has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Hepatology. Recurrent topics in Timothy Perera's work include Liver physiology and pathology (11 papers), Cancer Mechanisms and Therapy (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Timothy Perera is often cited by papers focused on Liver physiology and pathology (11 papers), Cancer Mechanisms and Therapy (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Timothy Perera collaborates with scholars based in Belgium, Italy and United Kingdom. Timothy Perera's co-authors include Paolo M. Comoglio, Carla Boccaccio, Gigliola Reato, Francesca De Bacco, Paolo Luraghi, P. Gabriele, Enzo Médico, Flavia Girolami, Stuart Kellie and Caroline Price and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Timothy Perera

29 papers receiving 1.2k citations

Peers

Timothy Perera
Siao Ping Tsai United States
Wenqing Yao United States
Alice Loo United States
Peter K. Harris United States
Sofia Loera United States
Yuji Chatani Japan
Andrea Murányi United States
Wendy W. Hwang‐Verslues Taiwan
Ruben Boon Belgium
Mónica Garcı́a-Barros United States
Siao Ping Tsai United States
Timothy Perera
Citations per year, relative to Timothy Perera Timothy Perera (= 1×) peers Siao Ping Tsai

Countries citing papers authored by Timothy Perera

Since Specialization
Citations

This map shows the geographic impact of Timothy Perera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Perera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Perera more than expected).

Fields of papers citing papers by Timothy Perera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Perera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Perera. The network helps show where Timothy Perera may publish in the future.

Co-authorship network of co-authors of Timothy Perera

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Perera. A scholar is included among the top collaborators of Timothy Perera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Perera. Timothy Perera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Krebs, Matthew, Ruth Plummer, Filip De Vos, et al.. (2023). A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer. The Oncologist. 28(12). e1248–e1258. 1 indexed citations
3.
Steenbrugge, Jonas, Kristel Demeyere, Timothy Perera, et al.. (2022). One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer. OncoImmunology. 11(1). 2103277–2103277. 14 indexed citations
4.
Terranova, Nadia, Kim Stuyckens, Anne‐Gaëlle Dosne, et al.. (2021). A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. Cancer Chemotherapy and Pharmacology. 89(1). 117–128. 10 indexed citations
5.
Steenbrugge, Jonas, Kristel Demeyere, Olivier De Wever, et al.. (2021). OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer. npj Breast Cancer. 7(1). 27–27. 6 indexed citations
6.
Martín, Valentina, Cristina Chiriaco, Chiara Modica, et al.. (2019). Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer. 120(5). 527–536. 35 indexed citations
7.
Mira, Alessia, Virginia Morello, María Virtudes Céspedes, et al.. (2017). Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. Oncotarget. 8(24). 38193–38213. 17 indexed citations
8.
Pupo, Emanuela, Barbara Lupo, Elisa Vigna, et al.. (2016). Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. Cancer Research. 76(17). 5019–5029. 20 indexed citations
9.
Bacco, Francesca De, Antonio D’Ambrosio, Elena Casanova, et al.. (2016). MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells. EMBO Molecular Medicine. 8(5). 550–568. 66 indexed citations
10.
Luraghi, Paolo, Gigliola Reato, Francesco Sassi, et al.. (2014). MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors. Cancer Research. 74(6). 1857–1869. 117 indexed citations
11.
Pennacchietti, Selma, Andrea Bertotti, William M. Rideout, et al.. (2014). Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs. Cancer Research. 74(22). 6598–6609. 55 indexed citations
12.
Musiani, Daniele, Francesco Sassi, Alessio Noghero, et al.. (2014). Heat‐shock protein 27 (HSP27, HSPB1) is up‐regulated by MET kinase inhibitors and confers resistance to MET‐targeted therapy. The FASEB Journal. 28(9). 4055–4067. 31 indexed citations
13.
Dienstmann, Rodrigo, Rastilav Bahleda, Bárbara Adamo, et al.. (2014). Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. Cancer Research. 74(19_Supplement). CT325–CT325. 21 indexed citations
14.
Torti, Davide, Francesco Sassi, Francesco Galimi, et al.. (2011). A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. International Journal of Cancer. 130(6). 1357–1366. 18 indexed citations
15.
Bacco, Francesca De, Paolo Luraghi, Enzo Médico, et al.. (2011). Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer. JNCI Journal of the National Cancer Institute. 103(8). 645–661. 282 indexed citations
16.
Scales, Timothy M.E., Pascal Derkinderen, Kit‐Yi Leung, et al.. (2011). Tyrosine Phosphorylation of Tau by the Src Family Kinases Lck and Fyn. Molecular Neurodegeneration. 6(1). 12–12. 46 indexed citations
17.
Perera, Timothy, Peter King, Laurence Mévellec, et al.. (2008). JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models.. Cancer Research. 68. 4837–4837. 20 indexed citations
18.
Reynolds, C. Hugh, Claire J. Garwood, Selina Wray, et al.. (2008). Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase Cγ1, Grb2, and Src Family Kinases. Journal of Biological Chemistry. 283(26). 18177–18186. 186 indexed citations
19.
Derkinderen, Pascal, Timothy M.E. Scales, Diane P. Hanger, et al.. (2005). Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. Journal of Neuroscience. 25(28). 6584–6593. 153 indexed citations
20.
Craggs, Graham, Peter M. Finan, Durward Lawson, et al.. (2001). A Nuclear SH3 Domain-binding Protein That Colocalizes with mRNA Splicing Factors and Intermediate Filament-containing Perinuclear Networks. Journal of Biological Chemistry. 276(32). 30552–30560. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Siao Ping Tsai Breakdown of academic impact, for papers by Wenqing Yao Breakdown of academic impact, for papers by Alice Loo Breakdown of academic impact, for papers by Peter K. Harris Breakdown of academic impact, for papers by Sofia Loera Breakdown of academic impact, for papers by Yuji Chatani Breakdown of academic impact, for papers by Andrea Murányi Breakdown of academic impact, for papers by Wendy W. Hwang‐Verslues Breakdown of academic impact, for papers by Ruben Boon Breakdown of academic impact, for papers by Mónica Garcı́a-Barros
Rankless by CCL
2026